Efficacy of intranasal administration of artesunate in experimental cerebral malaria by Anne Marijon et al.
Marijon et al. Malaria Journal 2014, 13:501
http://www.malariajournal.com/content/13/1/501RESEARCH Open AccessEfficacy of intranasal administration of artesunate
in experimental cerebral malaria
Anne Marijon1,2, Guillaume Bonnot1, Anthony Fourier3, Coralie Bringer1, Adeline Lavoignat1,
Marie-Claude Gagnieu3, Anne-Lise Bienvenu1,2 and Stéphane Picot1,2*Abstract
Background: Improving management of patients suffering from cerebral malaria is needed to reduce the
devastating mortality and morbidity of the disease in endemic areas. Intravenous artesunate is currently the first-line
treatment, but the lack of material and skills in the field make it difficult to implement in endemic areas. Intranasal
route provides a very easy and direct gateway to blood and brain to deliver medications, by-passing the brain
blood barrier. Therefore, it could be helpful and suitable to administer artesunate in the context of cerebral malaria,
especially in young children. In this study, intranasal administration of artesunate to rescue from cerebral malaria
using a murine model was tested.
Methods: CBA/J mice infected with Plasmodium berghei ANKA strain received artesunate (20 mg/kg) or a placebo
solution intranasally, either on day 5, 6 or 7 post-infection, during a controlled, blinded, randomized trial. Primary
endpoint was mortality on day 12 post-infection. Secondary endpoints were parasitaemia and clinical stage.
Pharmacokinetics data following administration were collected in blood and brains of treated mice. Local toxicity
was evaluated by histopathologic examination of brain and nasal sections in blinded manner.
Results: Intranasal administration of artesunate dramatically reduced the mortality rate (p < 0.001), preventing death
in most cases. Parasitaemia loads decreased by 88.7% (61.8-100%) within 24 hours after administration. Symptoms
of cerebral malaria were prevented or reversed. Dihydroartemisinin was detected in mice blood and brain within
15 minutes of intranasal administration. No direct nasal or brain toxicity was detected.
Conclusion: Intranasal delivery is an efficient route to timely and efficiently administer artesunate and therefore
may contribute to decreasing malaria-related mortality.
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Malaria still causes an unacceptable mortality rate in en-
demic areas and is responsible for more than half a mil-
lion deaths each year, mainly in sub-Saharan Africa and
in children under five years [1,2]. Without treatment,
cerebral malaria invariably leads to death, mostly within
the first 36 hours. Five to 30% of surviving children may
be left with neurological disabilities [3,4]. Eliminating* Correspondence: stephane.picot@univ-lyon1.fr
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unless otherwise stated.malaria requires preventing mosquito bites, making accur-
ate diagnosis, administering early treatment with good
drugs at the right dose, and future mass vaccination. Con-
siderable progress has been made, but malaria elimination
still needs universal access to these strategies. Bed nets are
insufficiently used in endemic areas, rapid diagnostic tests
and effective drugs are poorly available in remote areas
and malaria vaccine is far from being available. Cerebral
malaria is an emergency that requires early diagnostic and
care in order to prevent both fatal outcome and risk of
neurological sequelae.
Intravenous artesunate is currently the first-line ther-
apy since its superiority over quinine has been demon-
strated in large randomized trials [5,6]. Artesunate is a
water-soluble, semi-synthetic, artemisinin derivative. Itl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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broad specificity of action on the various stages of the
parasite. Its outstanding ability to rapidly kill circulating
ring-stage parasites, preventing their maturation and se-
questration in deep organs, including the brain, explains
its high efficiency to rescue severe malaria [7-9].
In endemic areas, most patients do not have access to
intense care units with trained medical staff; the intra-
venous route is difficult to implement in the field and
even more so in young children. In this context, intra-
venous administration of artesunate may be delayed or
made in a perilous manner and prognosis of patients is
even poorer. Rectal administration of artesunate is an
alternative route already available [10,11]. The World
Health Organization (WHO) recommends its use as pre-
referral treatment during transportation to an appropriate
care centre [12]. Some cultural concerns may limit its use
as observed in some endemic areas. The intrarectal route
allows a systemic absorption without brain-specific target-
ing. Moreover, a delayed diffusion with variation among
individuals are reported [13]. More effective methods are
urgently needed to improve the management of severe
malaria patients in remote areas of Africa.
The nasal mucosa’s high degree of vascularization and
high permeability enable systemic drug concentration
via this route, making intranasal (IN) drug administra-
tion attractive compared to oral and parenteral routes
[14,15]. The number of drugs administered via the nasal
route has increased. Among these, the most popular are
analgesics (morphine), migraine treatment (sumatriptan),
cardiovascular drugs (propranolol), hormones (progester-
one), anti-inflammatory drugs (indomethacin). Recently,
the key role of olfactory bulb (OLF) in the pathophysi-
ology of experimental cerebral malaria was demonstrated,
providing the first evidence that malaria-infected erythro-
cytes use OLF as a gateway to the brain [16]. The demon-
stration of Plasmodium berghei-infected red blood cell
sequestration in the brain promotes interest in experimen-
tal therapeutic cerebral malaria. Plasmodium berghei cere-
bral malaria rodent model is an experimental tool to study
new routes of drug administration.
Blood supply to the nasal cavity is provided by branches
of the ophthalmic artery (ethmoidal arteries in the olfac-
tory region), the splenopalatine artery, branches of the fa-
cial artery and extensive anastomoses in the Kiesselbach’s
plexus. The arterial blood flow irrigates a dense bed of ca-
pillaries and large venous sinusoids near the respiratory
zone. The venous return involves the splenopalatine, facial
and ophthalmic veins which drain via the superior vena
cava into the right heart chambers, and explain the ab-
sence of the hepatic first-pass effect [15]. The pharmacoki-
netic properties of drugs administered via IN route are
dependent on physicochemical properties of compounds
and on IN conditions, including mucociliary clearance,solution’s viscosity and volume administered. Variations in
inspiratory flow or rhinitis were shown to have only a
minor influence on the efficacy of deposition on the
turbinate zone [15].
IN drug administration offers a non-invasive method
that circumvents the blood–brain barrier (BBB) and pro-
vides rapid drug absorption for acute brain insults without
systemic side effects. This pathway is believed to involve
two general mechanisms. The first is internalization of the
drug into the primary neurons of the olfactory epithelium,
either by endocytotic or pinocytotic mechanisms, and
intracellular axonal transport to the OLF. The second is
an extracellular pathway that allows for rapid absorption
of the drug across the olfactory epithelial cells, either by
transcellular or paracellular mechanisms, followed by
uptake into the central nervous system.
It has been shown that molecules can take intracellular
and extracellular pathways alongside olfactory and trigem-
inal primary neurons located in the nasal mucosa. From
these singular neuronal extensions, drugs can directly
reach the OLF and the brainstem, followed by uptake into
the central nervous system.
IN route allow substances direct access to the brain.
Molecules might also pass in systemic circulation since
nasal cavity is highly vascular. Subsequently, IN route
allows timely and efficiently delivery of anti-malarial drugs
during cerebral malaria. While a preliminary study reported
years ago that prophylactic IN administration of dihydroar-
temisinin was as effective as the intraperitoneal route in
mice [17], this route has never been tested further.
The aim of this study was to test safety, pharmacokinetic
and efficacy of IN administration of artesunate in a murine
model of cerebral malaria. IN administration of artesunate
improved survival and symptoms of mice suffering from
severe malaria. It rapidly led to a decrease of blood parasit-
aemia. Artesunate and dihydroartemisinin were detected in
blood within 15 minutes of administration and no signifi-
cant local toxicity was observed. These results support the




Animal experiments were conducted in agreement with
ethical and general rules for animal protection. The ex-
perimental protocol was approved by the Committee of
Ethics of animal experiments of Lyon 1 University, France
(BH2012-82v2). Severe malaria was induced in female
CBA/J mice, weighing 18–20 g (Janvier Labs, Saint
Berthevin, France) by intraperitoneal inoculation of 106 P.
berghei ANKA parasitized erythrocytes stored into frozen ni-
trogen. Despite some differences, this model is the most
widely used animal model to study human cerebral malaria
since it shares some neurological signs and histopathological
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laboratory non-sterile food and tap water ad libitum.
Efficiency study
A blinded, randomized trial versus placebo was conducted.
On day 5 post-infection (pi), 54 mice were randomized
into four groups. A randomization table was edited by an
external experimenter who provided the solution (artesu-
nate or placebo) to administer intranasally to each mouse
and then did not participate in other steps of the study.
Three groups received a single IN administration of
artesunate (Guilin Pharmaceutical, Guangxi, China,
20 mg/kg) either on day 5 pi, 6 pi or 7 pi, and one control
group received a placebo solution intranasally either on
day 5 pi, 6 pi or 7 pi. Artesunate was prepared following
supplier instructions for intravenous use with sodium
bicarbonate and saline solution. Placebo was made up in
the same way without artesunate powder. IN deliveries
(6 μl in each nostril) were performed by pipetting after
complete anaesthesia with xylazine (3.75 mg/kg) and keta-
mine (75 mg/kg). Mice were maintained in standing pos-
ition until they recovered normal ventilation. Primary
endpoint was survival rates at day 12 pi. Secondary end-
points were parasitaemia courses and clinical evaluations.
Determinations of parasitaemia were done onto thin
blood smears made by vein tail incisions and stained by
Giemsa 10%. Parasitaemias were calculated as the arith-
metic mean of two independent readings by trained
operators (by counting the number of red blood cells
(RBCs) parasitized by viable parasite among at least
10,000 RBCs). Discrepancies were resolved by a third
reading and consensus between readers.
Bienvenu clinical score was used for clinical monitor-
ing [20]. Stage 0 indicated asymptomatic mice; stage 1,
unspecific symptoms (ruffled fur); stage 2, ruffled fur
and motor impairments; stage 3, hemiplegia and/or
respiratory distress; and, stage 4, coma and/or convulsions.
All mice were euthanized on day 12 pi according to
the protocol defined by the Committee of Ethics. The
randomization table was disclosed after the collection
of all data. Mice with parasitaemia lower than 0.01%
(approximately 103 parasites per μl) on day 5 pi were
discarded from the analysis. Results shown here are
consistent with those from three previous experiments.
Pharmacokinetic study
Forty-five mice were randomly divided into 15 experimental
groups of three animals each. Ten groups were parasitized
(as previously described) and five groups were kept healthy
in order to assess the impact of the disease on drug pro-
perties. Mice received artesunate (Guilin Pharmaceutical,
Guangxi, China, 20 mg/kg) intranasally on day 5 pi and were
sacrificed at predetermined time-point by cervical disloca-
tion (15 min, 30 min, 45 min, 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr,and 16 hr post-dosing). After euthanasia, blood samples and
brains were immediately collected. Blood samples were col-
lected into heparinized tubes (Vacutainer, Becton Dickinson
Diagnostics, Franklin Lakes, USA) and immediately centri-
fuged to separate plasma. Plasma and brains were kept fro-
zen at −80°C until drug quantification. Drug extraction was
done by mixing plasma or brain homogenates with aceto-
nitrile organic solvent. After centrifugation, supernatants
were collected and analysed. Artesunate and its active me-
tabolite, dihydroartemisinin, concentrations were determined
by ultra performance liquid chromatography with mass tan-
dem detector (UPLC-MS/MS) method on a Cortecs UPLC
column C18 (1.6 μm-2.1 × 75 mm, Waters, Milford, USA).
The run time of each sample was 4 min. Detection was
based on multiple reaction monitoring with precursor-to-
product ion transitions m/z 402.37-267.17 (artesunate), m/z
302.30-163.15 (dihydroartemisinin) and m/z 320.26-247.08
(chloroquine, used as internal standard).
Toxicity study
Local toxicity after IN administration of artesunate was
assessed by histopathology performed in blind manner in
collaboration with ANIPATH laboratory (Lyon 1 University,
France). Nine healthy CBA/J mice were treated intranasally
(as previously described) by either a placebo solution or a so-
lution of artesunate (Guilin Pharmaceutical, Guangxi, China,
20 mg/kg). Mice were sacrificed either 30 min (three control
mice and three treated mice) or two days (three treated
mice) post-dosing. Tissue samples (brain and face) were im-
mediately collected and post-fixed into formaldehyde 4%.
Face samples were decalcified in EDTA solution (10%) for
14 days. After embedment in paraffin and cutting, slides
were stained by haematoxylin phloxine saffron (HPS).
Sections were examined by a trained veterinary patholo-
gist in blind manner of the group of each mouse.
Statistical analysis
Statistical analyses were performed using R software ver-
sion 3.0.2. All values are expressed in means (+/− SEMs).
Cumulative survival rates were calculated according to
Kaplan-Meier method and groups were compared using
the log-rank test. Parasitaemia courses were compared by
analysis of variance ANOVA or non-parametric Kruskal-
Wallis test when variances were unequal. Parasitaemia be-
fore and 24 hours after treatment were compared by
paired student t-test. p-value <0.05 was considered to be
statistically significant.
Results
Intranasal administration of artesunate kills the parasite
and saves the mice
CBA/J mice infected with P. berghei ANKA provide a
highly reproducible disease leading to death on days 7–8
pi. The trial was blinded and randomized. Mice were
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placebo either on day 5 pi, day 6 pi or day 7 pi. Primary
endpoint was survival rate on day 12 pi. As expected, death
of control mice mostly occurred on day 8 pi. Treatment
with IN artesunate resulted in a highly significant improve-
ment in survival (Figure 1) compared with control mice.
Most treated mice (26/30) were still alive on day 12 pi. This
survival improvement was significant whatever the delay
between infection and treatment (log-rank test, treatment
on day 5 pi (n = 12): p = 1.58 10−7, day 6 pi (n = 8): p = 8.89
10−4, day 7 pi (n = 10) : p = 4.92 10−5). The efficiency of IN
administration of artesunate was similar in all treated groups
(p >0.05).
Parasitaemia courses for each group are shown in
Figure 2. Before treatment (on day 5 pi), mean parasit-
aemia was 2.8 +/− 1.0% and parasitaemia levels were simi-
lar in all groups (ANOVA, p = 0.893). Parasitaemia of
mice treated on day 5 pi decreased by 84.2% (61-100%)
within 24 hours of a single artesunate IN administration
(mean parasitaemia on day 6 pi = 0.46 +/− 0.23%. On day
6 pi, mice that had not yet been treated (from groups
treated on day 6 pi, 7 pi or placebo) showed mean parasit-
aemia of 8.1% +/−3.8%. Parasitaemia of mice treated on
day 6 decreased by 86.8% (22.6-100%) within 24 hours of
a single artesunate IN administration (mean parasitaemia
on day 7 pi = 1.15 +/− 0.64%).Figure 1 Cumulative survival analysis (Kaplan-Meier method). On day
artesunate (20 mg/kg). A control group received IN placebo on day 5 pi, 6
significant reduction of the mortality in all treated groups compared with c
p = 4.92 10−5). The efficiency of the treatment was similar in the three treat
indicates the time of treatment for each group, black line: control group, b
line: mice treated at day 7.On day 7 pi, mice that had not yet been treated under-
went mean parasitaemia of 9.5 +/−2.6%. Parasitaemia of
mice treated on day 7 pi decreased by 92.1% (66.7-100%)
within 24 hours of a single artesunate IN administration
(mean parasitaemia on day 8 pi = 0.69 +/− 0.49%).
Overall, a single IN administration of artesunate in para-
sitized mice resulted in a decrease of 88.7% (61.8%-100%)
of parasitaemia loads within 24 hours. As suspected, para-
sites escaped rapidly the single dose of artesunate and para-
sitaemia lastly increased progressively until day 12 pi
(Figure 3). The slope of parasite growth was lower than be-
fore treatment, and delayed mortality by five to seven days.Clinical presentation and outcome of infected mice
All mice exhibited a clinical stage 0 (indiscernible symp-
toms) on day 5 pi. Seventy-seven per cent of the placebo
group mice (control) died on day 8 pi (10/13) and 100%
were dead at the endpoint. Mice treated once at day 5 pi
did not develop severe symptoms until the end of the ex-
periment and all showed a favorable outcome (Figure 4).
When mice were treated once on day 6 pi, the trend was
to develop moderate symptoms on day 7 pi (clinical stages
1 or 2) and then to recover. One mouse died from acute
respiratory distress during anesthesia on day 6 pi and be-
fore the administration of the treatment. Most of the mice5 pi, 6 pi or 7 pi, mice received a single IN administration of
pi or 7 pi. The endpoint was day 12 pi. The log-rank test revealed a
ontrol group (day 5 pi: p = 1.58 10−7, day 6 pi: p = 8.89 10−4, day 7 pi:
ed groups (p > 0.05). ***: p <0.001, NS: non-significant, coloured arrows
lue line: mice treated at day 5, red line: mice treated at day 6, green
Figure 2 Parasitaemia courses after intranasal administration of artesunate. On day 5 pi, 6 pi or 7 pi, mice received a single IN
administration of artesunate (20 mg/kg). A control group received IN placebo solution either on day 5 pi, 6 pi or 7 pi. In all treated groups, the
treatment administration led to a significant decrease of parasitaemia by 88.7% (61.8-100%) within 24 hours. Parasitaemia were compared using
ANOVA on day 5 pi and Kruskal-Wallis test on day 6 pi, 7 pi and 8 pi. In control group, mice were mostly dead on day 8 pi (10/13) and none of
them was alive on day 11 pi. ***p <0.001, **p <0.01, NS: non-significant coloured arrows indicates the time of treatment for each group, black
line: control group, blue line: mice treated at day 5, red line: mice treated at day 6, green line: mice treated at day 7.
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symptoms and progressively recovered after treatment.
Artesunate is transformed to dihydroartemisin and
diffused in blood and brain after IN administration
Mean blood and brain concentration curves of artesunate
and its active metabolite, dihydroartemisinin (DHA), in
parasitized and uninfected CBA/J mice after IN treatment,
are shown in Figure 5. IN artesunate led to high initial
blood concentrations; 15 min after administration, meanFigure 3 Parasite clearance 24 hours after intranasal administration o
administration of artesunate (20 mg/kg). Parasitaemia before and 24 hours
Parasitaemia decreased by 84.2% in mice treated on day 5 pi (p = 5.6 × 10−
mice treated on day 7 pi (p = 3.1 × 10−5). *: p <0.05, ***: p <0.001.artesunate blood concentration was 306 μg/l (+/− 83 μg/l).
Subsequently, artesunate blood concentration rapidly
decreased, with an estimated half-life close to 15 min.
There was no difference between uninfected and infected
mice. Artesunate was rapidly converted to DHA, which
reached an average of 2,018 μg/l (+/− 738 μg/l) blood peak
concentration (Cmax) and then rapidly decreased, with an
estimated half-life of 15 min. In comparison with healthy
mice, there is a trend toward delayed metabolism of artesu-
nate in parasitized mice since DHA curve in parasitizedf artesunate. On day 5 pi, 6 pi or 7 pi, mice received a single IN
after treatment were compared using paired t student test.
6), by 86.8% in mice treated on day 6 pi (p = 0.016) and by 92.1% in
Figure 4 Clinical monitoring after intranasal administration of artesunate. On day 5 pi (a), 6 pi (b) or 7 pi (c), mice received a single IN
administration of artesunate (20 mg/kg). A control group received IN placebo solution (d) either on day 5 pi, 6 pi or 7 pi. Compared to control
group, IN administration of artesunate led to the absence of symptoms development (when treatment had been administered on day 5 pi) or to
a reversion of symptoms (when treatment had been administered on day 6 pi or 7 pi). Bienvenu clinical staging scale: Stage 0: asymptomatic
mice; stage 1: unspecific symptoms (ruffled fur); stage 2: ruffled fur and motor impairments; stage 3: hemiplegia and/or respiratory distress; stage
4: coma and/or convulsions. Coloured arrows indicates the time of treatment for each group. Each line represents one mouse.
Marijon et al. Malaria Journal 2014, 13:501 Page 6 of 10
http://www.malariajournal.com/content/13/1/501mice seems to be slightly shifted. This subtle trend cannot
be definitively interpreted due to the low number of mice
per group.
IN artesunate led to DHA brain diffusion. No artesunate
was detected in brains of mice treated intranasally with
artesunate. This finding suggests initial metabolism of arte-
sunate outside the brain, probably in nasal mucosa and
blood where esterase enzymes are present. The average
concentration of DHA in brains was about 60% of blood
concentrations. It reached a maximum of 1,019 ng/g
(+/− 345 ng/g) and followed blood concentration evolution.
Olfactory tissues and brain are not affected by IN
administration of artesunate
Healthy CBA/J mice were treated intranasally by either
artesunate (20 mg/kg) or a placebo solution. No relevant
clinical signs of local toxicity, as haemorrhage or necro-
sis, were observed during the experiment. Likewise, none
of the mice exhibited general signs of toxicity. No abnor-
malities in eating, breathing, movement, and behaviour
were observed after recovery from anaesthesia.
HPS-stained histopathological sections of brains and
nasopharynx were done to assess safety of the treatment at
tissue level. IN administration of artesunate did not caused
any damage in the respiratory epithelia and olfactory tissue
of treated mice, compared to placebo-treated mice. No
signs of acute mucosal toxicity [21], such as necrosis or
ulceration, was detected. Slight lymphoid infiltrates were
observed in the underlying lamina propria of the nasalcavity mucosa of four mice (Figure 6a), but this pattern
was not correlated with the administration of artesunate
(i.e., it was observed in both treated and placebo mice).
Histopathological sections of brains revealed no signifi-
cant signs of acute neurotoxicity. Some periventricular
lymphoid limited infiltrates, were seen in all brains with
no correlation with the type of treatment received by the
mouse (Figure 6b). One mouse, euthanized 30 min after
IN artesunate, had multifocal gliosis (proliferation of
astrocytes). This observation is not consistent with a
possible toxicity of IN artesunate. Gliosis is a scar of
brain parenchyma injury which may appear two to ten
days after cerebral tissue damage [22]. In all brains,
many artifacts known as dark neurons contracted and
intensely stained neurons were observed (Figure 6c).
This common artifact may be due to post-mortem ma-
nipulation of brain tissues prior to fixation and cannot
be interpreted as dying cells [23-25]. Moreover, since it
was observed in all mice, it is unlikely to be related to
the IN administration of artesunate. In summary, no
significant toxicity was observed in brains and nasal
tissues of mice treated intranasally with artesunate,
compared with placebo-treated mice.
Discussion
In cases of severe malaria, children may die within the
first 24–36 hours of the disease [6]. This short period of
time is one of the obstacles to a significant reduction in
malaria mortality. A pre-referral treatment suitable for
Figure 5 Artesunate and dihydroartemisinin blood and brain concentrations following intranasal administration of artesunate. (a) After
IN administration, artesunate (ARS) blood concentration reached a very early Cmax (Tmax less than 15 min) and then rapidly converted, showing
a short T1/2 (close to 15 min). DHA, its active metabolite, reached an early maximum between 15 and 30 min and then decreased with a T1/2
close to 15 min. (b) No ARS was detected in brains suggesting a prior metabolism before brain diffusion. DHA was detected in brain 15 min after
IN administration. DHA brain concentrations globally followed blood concentrations and were about 60% of these.
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route has been opened years ago with the artesunate sup-
positories development, with still limited uses. Children re-
covering from cerebral malaria are suffering neurological
sequelae with considerable medical, social and economic
impact. Parasites sequestered in the microcirculation of the
brain are responsible for brain injury. The IN route is the
shortest and most convenient way to deliver efficient drug
to the brain at the earliest time. The major involvement of
olfactory bulb in experimental cerebral malaria and its ini-
tial injury at the early phases of the disease provides more
evidence for using anti-malarial drugs via the IN route [16].
Artesunate has been proven to be the most effective drug
to rescue from cerebral malaria in both adults and children
[5,6,26]. WHO recommends its intravenous administrationimmediately when symptoms of severe malaria are de-
tected. Intravenous route ensures a reliable bioavailabil-
ity but it can be the origin of a delayed administration.
Parenteral delivery requires skills that are unavailable
or not easily reachable in local health centers. In re-
mote endemic areas, the delay before taking a seriously
ill and febrile child to a health care facility may often
be more than a day [27]. Alternative routes to provide
artesunate are available. Oral medication is inconveni-
ent in situations of severe malaria since patients might
exhibit loss of consciousness or vomiting. WHO calls
for the use of suppositories of artesunate as pre-referral
treatment during transport to an appropriate care center
[10-12]. Intrarectal route allows a systemic absorption,
without brain-specific targeting. Its pharmakokinetic
Figure 6 Haematoxylin phloxine saffron- stained histopathological sections from mice treated intranasally by artesunate (20 mg/kg).
(a) Nasal cavity section. This section shows a nasal fold lined by mucosal epithelium. On the first side, the nasal epithelium is normal with regular
ciliary lining cells (red star). On the other side, a little and confined cluster of lymphocytes and neutrophils (blue square) is present and nearby,
the epithelium is slightly inflammatory. The underlying lamina propria contains a minor lymphoid infiltrate (black cross). (b) Brain section through
a cerebral ventricule (red star). A lymphoid infiltrate is located in periventricular zone (black cross) without any injury of the neighbouring nervous
tissue and the ependimocyte border. (c) Brain section. Normal neuron bodies (arrow) are surrounded by neuropil. Dark neurons (arrowhead) are
common artifacts characterized as monomorphic contracted and intensively stained neurons. They do not represent degenerating cells.
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istration, but time delayed to Cmax, more than one hour,
has been reported. A lower bioavailability with high inter-
individual variability has been pointed out, compared to
intravenous route [13]. Moreover, this method of adminis-
tration may confront low acceptability in populations of
different cultures. IN delivery is an emerging route to de-
liver drugs, most notably when the brain is specifically tar-
geted [28-31]. In addition, to allow a systemic entry gate,
it offers a direct front door to the central nervous system
via the olfactory and trigeminal nerve terminations located
in the nasal mucosa. It has been shown that molecules
can take intracellular and extracellular pathways alongside
these singular neuronal extensions to directly reach the
brain [32]. Therefore, drugs can sidestep the BBB. It is an
easy, non-invasive route requiring no specific skills or
equipment, and therefore, could be appropriate in a rescue
context for cerebral malaria in the field.
In the present study, the efficiency of IN administration
of artesunate in a murine experimental model of severe
malaria was assessed. IN route in mouse models raises
some issues. Given the small size of the animals and diffi-
culty of handling, IN administration was done by pipetting6 μl in each nostril under anaesthesia. Therefore, it cannot
be excluded that a small proportion of the dose was swal-
lowed or inhaled. However, this may similarly occur
during human administration. Anatomical differences
between mice and human should be considered [32,21].
Rodents are obligate nasal breathers and macrosmatic.
The relatively higher surface of their nasal cavity and the
higher percentage of olfactive epithelium could improve
the passage of drugs through their nasal mucosa. The
efficiency and the modalities of IN administration need to
be precisely assessed in humans.
IN artesunate was highly effective in saving mice, in
both early and late stages of the disease. Even adminis-
tered later than 24 hours before the death of control mice
and/or in mice displaying advanced stages of the disease,
IN artesunate prevents death in most cases. Parasitaemia
levels cuts around 89% within the first 24 hours after a
single IN administration of artesunate. This result corre-
lates with decreases close to 70% described in the litera-
ture after intraperitoneal administration of artesunate at
higher dosages (32 mg/kg or 64 mg/kg) [18]. Thus, IN
route proved its efficiency to deliver artesunate. These
results are in accordance with Touitou et al. [17] who
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tered in prophylaxis was at least as effective as the in-
traperitoneal route to save parasitized mice from death.
Pharmacokinetics data showed early diffusion of DHA
following IN administration of artesunate. Cmax in blood
and brains was obtained 15 to 30 min after treatment.
This observation supports the hypothesis of better effi-
ciency of the IN route compared to rectal route. Direct
nose-to-brain drug passage may have occurred when arte-
sunate is administered intranasally but high levels of DHA
were found in treated mice brains. Jain et al. [33] investi-
gated IN administration of arthemether-loaded nanolipid
carriers on healthy rats, showing a direct nose-to-brain
transport, with higher brain to blood ratios compared to
intravenous administration.
Artesunate is safe and no serious acute side effects were
reported in human trials [5,6]. Nasal and cerebral toxicity
induced by IN artesunate were not detected. Long-term
exposure to high doses of artesunate can induce cell tox-
icity [34]. IN administration allows rapid absorption with
a short mucosal exposure to the drug. The early elimin-
ation of the drug in blood and brain is similar to blood
clearance described for intravenous route.
IN administration of artesunate might be helpful in
rapid rescue from death but a recrudescence of parasite
always occurs since artemisinin derivatives given alone
provide only an approximate 20% cure rate [35]. Rescu-
ing therapy based on an artemisinin derivative should be
followed by artemisinin-based combination therapy
(ACT). IN artesunate could be used as a pre-referral
treatment. The IN administration of ACT deserves to be
addressed. Altogether, these data open new opportun-
ities for malaria-rescuing treatment in endemic areas. It
is expected that phase I-II clinical trials could be con-
ducted in humans in the near future to confirm that evi-
dence. Devices to administer correctly artesunate are
available from different providers in the market, and sta-
bility tests will be soon available. Advices for correct
drug administration in the patient nostrils will be needed
during the design of future clinical trials.
For the first time, it was demonstrated that IN delivery
is highly effective to treat experimental murine severe
malaria in both early and advanced stages of the disease.
This finding provides a hopeful way to improve severe
malaria rescue treatment in endemic areas. Indeed, early
IN administration of the drug might very easily be done
without specific skills, to save time over disease pro-
gression and reduce malaria-related mortality.
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